Emergent gets $23 million additional order for vaccine production

April 5, 2021 BIO, Company News, Content produced in Bangalore, Coronavirus, EMERGENT, epidemics, Europe, health, S, U, United Kingdom, US

FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance.

Source: Read Full Article

China Builds Permanent COVID Testing Stations for Life After Lockdown

Ethics of mandatory vaccinations: Benefits may not outweigh challenges

Weight loss: Good sleep may be key to greater adherence